A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.

Daijiro HaradaToshiyuki KozukiNaoyuki NogamiAkihiro BesshoShinobu HosokawaNobuaki FukamatsuKatsuyuki HottaKadoaki OhashiToshio KuboHiroshige YoshiokaToshihide YokoyamaNaoyuki SoneShoichi KuyamaKenichiro KudoMasayuki YasugiNagio TakigawaIsao OzeKatsuyuki Kiura

Published in: Asia-Pacific journal of clinical oncology (2019)

This study failed to meet predefined primary endpoints for pretreated patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.

Keyphrases

epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
diffuse large b cell lymphoma
single cell
protein kinase
clinical trial
study protocol
cell therapy
phase iii
randomized controlled trial
stem cells
bone marrow
open label
chemotherapy induced